Drug Combo Proves Powerful Against Lung Cancer New Paltz NY

A two-drug combination treatment in New Paltz proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Javier Ruiz
(845) 565-9800
3141 Us Route 9w
New Windsor, NY
JASON RUBIN, MD
(845) 231-5600
600 Westage Business Ctr Drive
Fishkill, NY
GLENN AGOLIATI, MD
(845) 454-1942
19 Baker Avenue
Poughkeepsie, NY
FAUZIA PARACHA, MD
(845) 562-6240
327 Fullerton Avenue
Newburgh, NY
Robert L McKee, MD
914-896-6203
7 Fair Oaks Dr
Poughkeepsie, NY
Zoe A Weinstein
(845) 876-7095
91 Montgomery St
Rhinebeck, NY
Javier A Ruiz, MD
(845) 561-4450
59 New Windsor Hwy Rte 32
New Windsor, NY
NILOUFER RODRIGUES, MD
(845) 454-1942
1 Webster Avenue
Poughkeepsie, NY
VANITA NORONHA, MD
(845) 561-7455
407 Gidney Avenue
Newburgh, NY
Edward Mehdi Farhangi, MD
845-454-2372
45 Reade Pl
Poughkeepsie, NY
Data Provided by:
      

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Risks for Childhood Cancer Survivors New Paltz NY
People who survived cancer as children face a high lifelong risk for developing another cancer, a new study has found. A study that appears online May 26 in the Journal of the National Cancer Institute went further than earlier studies by following people from birth through age 79. The researchers analyzed data on more than 47,000 people who had been diagnosed with cancer before the age of 20.
- Exercise for Prostate Cancer New Paltz NY
- Genetic Clues for Skin Cancer Therapies New Paltz NY
- Hormone Therapy for Lung Cancer New Paltz NY
- Delayed Prostate Cancer Therapy New Paltz NY
- Hormone Therapy for Breast Cancer New Paltz NY
- Fungal Infection Treatments New Paltz NY
- Side Effect Of Chemotherapy Drugs New Paltz NY
- Exercise for Breast Cancer Survival New Paltz NY